Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended September 30, 2024
Business Overview: The company operates in two primary segments: private-label contract manufacturing for nutritional supplements and patent/trademark licensing for beta-alanine ingredients (CarnoSyn®). The company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Q1 2025 (Sep 30, 2024) | Q1 2024 (Sep 30, 2023) |
|---|---|---|
| Net Sales | $33.15 million | $33.97 million |
| Gross Profit | $2.26 million | $3.14 million |
| Gross Margin | 6.8% | 9.2% |
| Loss from Operations | $(1.84) million | $(0.54) million |
| Net Loss | $(1.98) million | $(0.70) million |
| Diluted EPS | $(0.33) | $(0.12) |
| Cash and Equivalents | $10.16 million | $16.75 million (End of Period) |
| Operating Cash Flow | $(3.44) million | $4.50 million |
| Total Debt (Line of Credit + Term Loan) | $14.6 million | $12.6 million (Est. based on prior period) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 2% year-over-year. Private-label contract manufacturing sales dropped 5% due to reduced orders from a major customer, partially offset by growth in the patent and trademark licensing segment, which rose 42% to $2.52 million.
- Margin Compression: Gross margin contracted from 9.2% to 6.8%. This was driven by an unfavorable sales mix shift and increased manufacturing costs (labor, supplies, rent, and freight).
- Increased Losses: Net loss widened by 185% to $1.98 million. Operating expenses increased 11% due to higher compensation and legal fees. Other expenses rose 70% primarily due to foreign exchange losses ($0.43 million) and higher interest costs.
- Cash Flow Reversal: Operating cash flow swung from a positive $4.5 million in the prior year to a negative $3.4 million, driven by inventory build-up ($1.7 million usage) and reduced collections timing.
Outlook, Risks, and Management Commentary
- Financial Covenant Breach: The company was not in compliance with net income requirements under its credit facility as of September 30, 2024. Management anticipates non-compliance in the next two quarters regarding net income and fixed charge coverage ratios. They are currently negotiating a waiver or revised facility with Wells Fargo.
- Guidance: Management anticipates a net loss in the first half of fiscal 2025, net income in the second half, but an overall net loss for the full fiscal year 2025.
- Strategic Initiatives: The company is launching "TriBsyn™," a new beta-alanine product designed to eliminate paresthesia, targeting the wellness and healthy aging markets. They aim to diversify the customer base to reduce reliance on top private-label clients.
- Risks: Significant risks include geopolitical instability (Israel-Hamas/Hezbollah conflict) affecting raw material sourcing and supply chains, customer concentration (top customer represents 37% of sales), and the uncertainty of securing a credit facility waiver.
Investor Verification Checklist
- Credit Facility Status: Verify the outcome of negotiations with Wells Fargo regarding the covenant waiver and potential terms of a revised credit facility.
- Liquidity Runway: Confirm if the current cash balance ($10.2 million) and remaining credit capacity ($7.1 million) are sufficient to fund operations through the anticipated loss period in H1 2025.
- Customer Concentration: Monitor the stability of the top customer (37% of sales) and the success of diversification efforts.
- Product Adoption: Assess early market reception and sales traction for the new TriBsyn™ product.
- Geopolitical Impact: Evaluate any supply chain disruptions or cost increases resulting from conflicts in the Middle East affecting raw material sourcing.